首页 > 最新文献

World Journal of Surgical Oncology最新文献

英文 中文
Impact of histopathological subtypes on invasive lung adenocarcinoma: from epidemiology to tumour microenvironment to therapeutic strategies.
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2025-02-27 DOI: 10.1186/s12957-025-03701-9
Shaowei Xin, Miaomiao Wen, Yahui Tian, Honghong Dong, Zitong Wan, Suxin Jiang, Fancheng Meng, Yanlu Xiong, Yong Han

Lung adenocarcinoma is the most prevalent type of lung cancer, with invasive lung adenocarcinoma being the most common subtype. Screening and early treatment of high-risk individuals have improved survival; however, significant differences in prognosis still exist among patients at the same stage, especially in the early stages. Invasive lung adenocarcinoma has different histological morphologies and biological characteristics that can distinguish its prognosis. Notably, several studies have found that the pathological subtypes of invasive lung adenocarcinoma are closely associated with clinical treatment. This review summarised the distribution of various pathological subtypes of invasive lung adenocarcinoma in the population and their relationship with sex, smoking, imaging features, and other histological characteristics. We comprehensively analysed the genetic characteristics and biomarkers of the different pathological subtypes of invasive lung adenocarcinoma. Understanding the interaction between the pathological subtypes of invasive lung adenocarcinoma and the tumour microenvironment helps to reveal new therapeutic targets for lung adenocarcinoma. We also extensively reviewed the prognosis of various pathological subtypes and their effects on selecting surgical methods and adjuvant therapy and explored future treatment strategies.

{"title":"Impact of histopathological subtypes on invasive lung adenocarcinoma: from epidemiology to tumour microenvironment to therapeutic strategies.","authors":"Shaowei Xin, Miaomiao Wen, Yahui Tian, Honghong Dong, Zitong Wan, Suxin Jiang, Fancheng Meng, Yanlu Xiong, Yong Han","doi":"10.1186/s12957-025-03701-9","DOIUrl":"https://doi.org/10.1186/s12957-025-03701-9","url":null,"abstract":"<p><p>Lung adenocarcinoma is the most prevalent type of lung cancer, with invasive lung adenocarcinoma being the most common subtype. Screening and early treatment of high-risk individuals have improved survival; however, significant differences in prognosis still exist among patients at the same stage, especially in the early stages. Invasive lung adenocarcinoma has different histological morphologies and biological characteristics that can distinguish its prognosis. Notably, several studies have found that the pathological subtypes of invasive lung adenocarcinoma are closely associated with clinical treatment. This review summarised the distribution of various pathological subtypes of invasive lung adenocarcinoma in the population and their relationship with sex, smoking, imaging features, and other histological characteristics. We comprehensively analysed the genetic characteristics and biomarkers of the different pathological subtypes of invasive lung adenocarcinoma. Understanding the interaction between the pathological subtypes of invasive lung adenocarcinoma and the tumour microenvironment helps to reveal new therapeutic targets for lung adenocarcinoma. We also extensively reviewed the prognosis of various pathological subtypes and their effects on selecting surgical methods and adjuvant therapy and explored future treatment strategies.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"66"},"PeriodicalIF":2.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical comparative study of the modified superior mesenteric artery approach in total laparoscopic radical resection for right colon cancer - a single-center retrospective study.
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2025-02-27 DOI: 10.1186/s12957-025-03725-1
Lishuai Xu, Jiawei Wang, Yue Peng, Chengwei Wu, Song Wang, Xu Zhang, Changming Liang, Senlin Wan, Cheng Yang, Qingsheng Fu, Yabin Xia, Xiaoxu Huang, Li Xu

Background: To explore the safety and feasibility of the modified approach for accessing the superior mesenteric artery (SMA) in total laparoscopic radical resection for right colon cancer.

Methods: This single-center retrospective study included 107 patients who underwent total laparoscopic radical resection of right colon cancer at The First Affiliated Hospital of Wannan Medical College between August 2022 and December 2023. 53 patients were in the modified SMA approach (modified group) and 54 patients were in the traditional SMA approach (control group). The control group and modified group underwent total laparoscopic radical resection of right colon cancer, and the following baseline and pathological characteristics of the two groups were compared: intraoperative condition, postoperative recovery, and postoperative complications. Our modified surgical method was to isolate the mesocolon using a cranial(the ligament of Treitz) -to- caudal(the pedicle of ileocolic) pathway and the orderly ligation of blood vessels in the SMA.

Results: There was no statistically significant difference in the baseline characteristics or pathological data between the two groups. Compared with the traditional SMA approach, the modified SMA approach had a shorter surgical time(P < 0.001) and vascular dissection time (P < 0.001) and less intraoperative blood loss (P = 0.000). There was no statistically significant difference in the number of total harvested lymph nodes or positive harvested lymph nodes between the two groups of patients (P > 0.05); There was no statistically significant difference in postoperative hospital stay, time to first flatus, time to pull out drainage tube and drainage between the two groups of patients (P > 0.05), and there was no statistically significant difference in the incidence of complications between the two groups of patients (P > 0.05).

Conclusion: The modified SMA approach in totally laparoscopic radical resection for right colon cancer can shorten the surgical and vascular dissection time, reduce intraoperative bleeding and reduce the surgical difficulty and intraoperative risk of the SMA approach for right colon cancer. In clinical practice, its safety and feasibility are relatively high, and it is worth promoting.

Trial registration: The study was approved by the Ethics Committee of The First Affiliated Hospital of Wannan Medical College and registered with the China Clinical Trials Registry (ChiCTR2300075919, Date of Registration:2023-09-19- retrospective registration) http://www.chictr.org.cn/index.aspx .

{"title":"Clinical comparative study of the modified superior mesenteric artery approach in total laparoscopic radical resection for right colon cancer - a single-center retrospective study.","authors":"Lishuai Xu, Jiawei Wang, Yue Peng, Chengwei Wu, Song Wang, Xu Zhang, Changming Liang, Senlin Wan, Cheng Yang, Qingsheng Fu, Yabin Xia, Xiaoxu Huang, Li Xu","doi":"10.1186/s12957-025-03725-1","DOIUrl":"10.1186/s12957-025-03725-1","url":null,"abstract":"<p><strong>Background: </strong>To explore the safety and feasibility of the modified approach for accessing the superior mesenteric artery (SMA) in total laparoscopic radical resection for right colon cancer.</p><p><strong>Methods: </strong>This single-center retrospective study included 107 patients who underwent total laparoscopic radical resection of right colon cancer at The First Affiliated Hospital of Wannan Medical College between August 2022 and December 2023. 53 patients were in the modified SMA approach (modified group) and 54 patients were in the traditional SMA approach (control group). The control group and modified group underwent total laparoscopic radical resection of right colon cancer, and the following baseline and pathological characteristics of the two groups were compared: intraoperative condition, postoperative recovery, and postoperative complications. Our modified surgical method was to isolate the mesocolon using a cranial(the ligament of Treitz) -to- caudal(the pedicle of ileocolic) pathway and the orderly ligation of blood vessels in the SMA.</p><p><strong>Results: </strong>There was no statistically significant difference in the baseline characteristics or pathological data between the two groups. Compared with the traditional SMA approach, the modified SMA approach had a shorter surgical time(P < 0.001) and vascular dissection time (P < 0.001) and less intraoperative blood loss (P = 0.000). There was no statistically significant difference in the number of total harvested lymph nodes or positive harvested lymph nodes between the two groups of patients (P > 0.05); There was no statistically significant difference in postoperative hospital stay, time to first flatus, time to pull out drainage tube and drainage between the two groups of patients (P > 0.05), and there was no statistically significant difference in the incidence of complications between the two groups of patients (P > 0.05).</p><p><strong>Conclusion: </strong>The modified SMA approach in totally laparoscopic radical resection for right colon cancer can shorten the surgical and vascular dissection time, reduce intraoperative bleeding and reduce the surgical difficulty and intraoperative risk of the SMA approach for right colon cancer. In clinical practice, its safety and feasibility are relatively high, and it is worth promoting.</p><p><strong>Trial registration: </strong>The study was approved by the Ethics Committee of The First Affiliated Hospital of Wannan Medical College and registered with the China Clinical Trials Registry (ChiCTR2300075919, Date of Registration:2023-09-19- retrospective registration) http://www.chictr.org.cn/index.aspx .</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"67"},"PeriodicalIF":2.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Body composition analysis using CT at three aspects of the lumbar third vertebra and its impact on the diagnosis of sarcopenia.
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2025-02-26 DOI: 10.1186/s12957-024-03634-9
Hui Yang, Zekan Gao, Qingzheng Shen, Huaiqing Zhi, Wentao Cai, Xiang Wang, Xiaodong Chen, Xian Shen, Weiteng Zhang

Purpose: The European Working Group on Sarcopenia in Older People (EWGSOP) revised the consensus in 2018, including that using computed tomography (CT) imaging of the lumbar third vertebra (L3) for the evaluation of muscle mass. However, there is currently discrepancy and confusion in the application of specific cross-sectional and cutoff values for L3. This study aimed to standardize the diagnosis of low muscle mass using L3-CT.

Materials and methods: This study included patients who underwent radical gastrectomy for gastric cancer between July 2014 and February 2019. Sarcopenia factors were measured preoperatively. Patients were followed up to obtain actual clinical outcomes. We used the cutoff values obtained based on the inferior aspect of L3-CT images to diagnose sarcopenia in three aspects, respectively. Univariate and multivariate analyses were used to compare long-term and short-term postoperative prognostic differences.

Results: Sarcopenia was found to be an independent risk factor for postoperative complications and overall survival in patients with all three diagnoses of sarcopenia. According to the multivariate model for predicting postoperative complications, patients with inferior-L3 sarcopenia (n = 154,13.8%) had a greater odds ratio (OR) than patients with superior-L3 sarcopenia (n = 220,19.7%) or transverse-L3 sarcopenia (n = 194,17.4%) did (OR, inferior sarcopenia vs. superior sarcopenia, transverse sarcopenia, 2.030 vs. 1.608, 1.679). Furthermore, patients with inferior-L3 sarcopenia had the highest hazard ratio (HR) (HR, inferior sarcopenia vs. superior sarcopenia, transverse sarcopenia, 1.491 vs. 1.408, 1.376) in the multivariate model for predicting overall survival.

Conclusion: We recommend that when diagnosing low muscle mass using L3-CT, the intercepted cross section should be uniform and consistent with the aspect on which the cutoff value is based.

{"title":"Body composition analysis using CT at three aspects of the lumbar third vertebra and its impact on the diagnosis of sarcopenia.","authors":"Hui Yang, Zekan Gao, Qingzheng Shen, Huaiqing Zhi, Wentao Cai, Xiang Wang, Xiaodong Chen, Xian Shen, Weiteng Zhang","doi":"10.1186/s12957-024-03634-9","DOIUrl":"10.1186/s12957-024-03634-9","url":null,"abstract":"<p><strong>Purpose: </strong>The European Working Group on Sarcopenia in Older People (EWGSOP) revised the consensus in 2018, including that using computed tomography (CT) imaging of the lumbar third vertebra (L3) for the evaluation of muscle mass. However, there is currently discrepancy and confusion in the application of specific cross-sectional and cutoff values for L3. This study aimed to standardize the diagnosis of low muscle mass using L3-CT.</p><p><strong>Materials and methods: </strong>This study included patients who underwent radical gastrectomy for gastric cancer between July 2014 and February 2019. Sarcopenia factors were measured preoperatively. Patients were followed up to obtain actual clinical outcomes. We used the cutoff values obtained based on the inferior aspect of L3-CT images to diagnose sarcopenia in three aspects, respectively. Univariate and multivariate analyses were used to compare long-term and short-term postoperative prognostic differences.</p><p><strong>Results: </strong>Sarcopenia was found to be an independent risk factor for postoperative complications and overall survival in patients with all three diagnoses of sarcopenia. According to the multivariate model for predicting postoperative complications, patients with inferior-L3 sarcopenia (n = 154,13.8%) had a greater odds ratio (OR) than patients with superior-L3 sarcopenia (n = 220,19.7%) or transverse-L3 sarcopenia (n = 194,17.4%) did (OR, inferior sarcopenia vs. superior sarcopenia, transverse sarcopenia, 2.030 vs. 1.608, 1.679). Furthermore, patients with inferior-L3 sarcopenia had the highest hazard ratio (HR) (HR, inferior sarcopenia vs. superior sarcopenia, transverse sarcopenia, 1.491 vs. 1.408, 1.376) in the multivariate model for predicting overall survival.</p><p><strong>Conclusion: </strong>We recommend that when diagnosing low muscle mass using L3-CT, the intercepted cross section should be uniform and consistent with the aspect on which the cutoff value is based.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"64"},"PeriodicalIF":2.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spread through air spaces may predict early progression after salvage surgery for EGFR-mutant advanced lung adenocarcinoma treated with targeted therapy.
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2025-02-26 DOI: 10.1186/s12957-025-03707-3
Yu-Wei Liu, Wei-An Lai, Jen-Yu Hung, Yen-Lung Lee, Hung-Hsing Chiang, Jui-Ying Lee, Hsien-Pin Li, Shah-Hwa Chou, Chih-Jen Yang

Objective: Salvage resection for residual lung cancer harboring epidermal growth factor receptor (EGFR) mutations following EGFR-tyrosine kinase inhibitor (TKI) treatment is gaining traction for its survival benefits. However, the impact of pathological factors on survival remains unclear.

Methods: Between 2013 and 2023, we retrospectively reviewed 34 patients with advanced lung adenocarcinoma who received EGFR-TKI therapy. After a median TKI treatment duration of 9.1 months, all patients demonstrated either partial response (n = 27) or stable disease (n = 7) before salvage surgery. Demographic, pathological outcomes, progression-free survival (PFS), and overall survival (OS) were analyzed.

Results: Among the 34 patients, six (17.6%) achieved a pathological complete response (pCR) and nine (26.5%) had a major pathological response (MPR). Additionally, 11 patients (32.4%) exhibited spread through air spaces (STAS), and lymphovascular invasion (LVI) was observed in nine patients (26.5%). The 3-year PFS and OS rates were 55.8% and 60.5%, respectively. No significant differences in PFS or OS were observed regarding mutation type, TKI generation, pCR, MPR, or LVI. However, Kaplan-Meier analysis revealed that STAS was associated with shorter PFS compared to non-STAS cases (p = 0.01). In multivariate analysis, STAS was identified as an independent prognostic factor for PFS (hazard ratio: 2.83, 95% CI: 1.35-28.54, p = 0.02). No significant prognosticators were found for OS in univariate or multivariate analyses.

Conclusion: While salvage surgery following TKI treatment is feasible and prolongs survival by removing residual primary tumor with potential TKI resistance, STAS may contribute to a higher risk of early progression. This finding warrants further investigation and tailored treatment strategies.

{"title":"Spread through air spaces may predict early progression after salvage surgery for EGFR-mutant advanced lung adenocarcinoma treated with targeted therapy.","authors":"Yu-Wei Liu, Wei-An Lai, Jen-Yu Hung, Yen-Lung Lee, Hung-Hsing Chiang, Jui-Ying Lee, Hsien-Pin Li, Shah-Hwa Chou, Chih-Jen Yang","doi":"10.1186/s12957-025-03707-3","DOIUrl":"10.1186/s12957-025-03707-3","url":null,"abstract":"<p><strong>Objective: </strong>Salvage resection for residual lung cancer harboring epidermal growth factor receptor (EGFR) mutations following EGFR-tyrosine kinase inhibitor (TKI) treatment is gaining traction for its survival benefits. However, the impact of pathological factors on survival remains unclear.</p><p><strong>Methods: </strong>Between 2013 and 2023, we retrospectively reviewed 34 patients with advanced lung adenocarcinoma who received EGFR-TKI therapy. After a median TKI treatment duration of 9.1 months, all patients demonstrated either partial response (n = 27) or stable disease (n = 7) before salvage surgery. Demographic, pathological outcomes, progression-free survival (PFS), and overall survival (OS) were analyzed.</p><p><strong>Results: </strong>Among the 34 patients, six (17.6%) achieved a pathological complete response (pCR) and nine (26.5%) had a major pathological response (MPR). Additionally, 11 patients (32.4%) exhibited spread through air spaces (STAS), and lymphovascular invasion (LVI) was observed in nine patients (26.5%). The 3-year PFS and OS rates were 55.8% and 60.5%, respectively. No significant differences in PFS or OS were observed regarding mutation type, TKI generation, pCR, MPR, or LVI. However, Kaplan-Meier analysis revealed that STAS was associated with shorter PFS compared to non-STAS cases (p = 0.01). In multivariate analysis, STAS was identified as an independent prognostic factor for PFS (hazard ratio: 2.83, 95% CI: 1.35-28.54, p = 0.02). No significant prognosticators were found for OS in univariate or multivariate analyses.</p><p><strong>Conclusion: </strong>While salvage surgery following TKI treatment is feasible and prolongs survival by removing residual primary tumor with potential TKI resistance, STAS may contribute to a higher risk of early progression. This finding warrants further investigation and tailored treatment strategies.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"65"},"PeriodicalIF":2.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interfering with UBE2L3 expression targets regulation of MLKL to promote necroptosis inhibition of growth in osteosarcoma.
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2025-02-24 DOI: 10.1186/s12957-025-03715-3
Xiwu Zhao, Guoqiang Shan, Deguo Xing, Hongwei Gao, Zhenggang Xiong, Wenpeng Hui, Mingzhi Gong

Background: In previous studies, elevated expression of UBE2L3 has been observed in osteosarcoma cells, and silencing UBE2L3 has been shown to promote oxidative stress and induce necroptosis. However, the exact molecular mechanisms underlying these findings remain unclear.

Objective: The purpose of this study is to investigate the molecular mechanisms by which interfering with UBE2L3 expression promotes necroptosis and impacts the progression of osteosarcoma, building upon previous in vitro cell experiments.

Methods: Osteosarcoma cells were transfected with shNC and shUBE2L3 plasmids, and the cells were injected into the right tibia of nude mice to establish a tumor xenograft model. The growth rate, changes in body weight, and tumor volume of the mice in each group were observed. After 15 days, the mice were sacrificed, and the tumors were dissected and analyzed for tumor volume. Immunohistochemical staining was performed to detect changes in the expression of necroptosis-related proteins, such as PCNA, p-MLKL, and p-RIP1. Additionally, U2OS and HOS cells were transfected with UBE2L3-silencing plasmids, and immunoprecipitation was performed to investigate the interaction between UBE2L3 and the necroptosis protein MLKL. By combining these experiments, we aim to evaluate the impact of UBE2L3 on necroptosis both in vitro and in vivo and elucidate its specific role in targeting MLKL to regulate necroptosis as a therapeutic approach for osteosarcoma.

Results: After interfering with UBE2L3, the growth rate of tumors in nude mice significantly slowed down, accompanied by a notable reduction in tumor volume and weight. These findings suggest that inhibiting the expression of UBE2L3 can suppress the growth of osteosarcoma. Furthermore, immunohistochemical analysis revealed that following UBE2L3 interference, the intensity of staining for the necrotic proteins p-MLKL and p-RIP1 was increased and PCNA staining was decreased, indicating that interfering with UBE2L3 expression can promote necroptosis. Moreover, through transfection of UBE2L3 silencing plasmids into osteosarcoma cells in vitro, immunoprecipitation and ubiquitination results demonstrated that UBE2L3 can specifically bind to MLKL. Overexpression of UBE2L3 promoted the ubiquitination of MLKL and reduced its expression. Thus, down-regulation of UBE2L3 could modulate downstream MLKL expression and promote necrosis of osteosarcoma cells.

Conclusion: UBE2L3 selectively binds to MLKL, exerting ubiquitination-mediated regulation on downstream MLKL. Decreased expression of UBE2L3 modulates MLKL expression and promotes necrosis, thereby inhibiting osteosarcoma growth.

{"title":"Interfering with UBE2L3 expression targets regulation of MLKL to promote necroptosis inhibition of growth in osteosarcoma.","authors":"Xiwu Zhao, Guoqiang Shan, Deguo Xing, Hongwei Gao, Zhenggang Xiong, Wenpeng Hui, Mingzhi Gong","doi":"10.1186/s12957-025-03715-3","DOIUrl":"10.1186/s12957-025-03715-3","url":null,"abstract":"<p><strong>Background: </strong>In previous studies, elevated expression of UBE2L3 has been observed in osteosarcoma cells, and silencing UBE2L3 has been shown to promote oxidative stress and induce necroptosis. However, the exact molecular mechanisms underlying these findings remain unclear.</p><p><strong>Objective: </strong>The purpose of this study is to investigate the molecular mechanisms by which interfering with UBE2L3 expression promotes necroptosis and impacts the progression of osteosarcoma, building upon previous in vitro cell experiments.</p><p><strong>Methods: </strong>Osteosarcoma cells were transfected with shNC and shUBE2L3 plasmids, and the cells were injected into the right tibia of nude mice to establish a tumor xenograft model. The growth rate, changes in body weight, and tumor volume of the mice in each group were observed. After 15 days, the mice were sacrificed, and the tumors were dissected and analyzed for tumor volume. Immunohistochemical staining was performed to detect changes in the expression of necroptosis-related proteins, such as PCNA, p-MLKL, and p-RIP1. Additionally, U2OS and HOS cells were transfected with UBE2L3-silencing plasmids, and immunoprecipitation was performed to investigate the interaction between UBE2L3 and the necroptosis protein MLKL. By combining these experiments, we aim to evaluate the impact of UBE2L3 on necroptosis both in vitro and in vivo and elucidate its specific role in targeting MLKL to regulate necroptosis as a therapeutic approach for osteosarcoma.</p><p><strong>Results: </strong>After interfering with UBE2L3, the growth rate of tumors in nude mice significantly slowed down, accompanied by a notable reduction in tumor volume and weight. These findings suggest that inhibiting the expression of UBE2L3 can suppress the growth of osteosarcoma. Furthermore, immunohistochemical analysis revealed that following UBE2L3 interference, the intensity of staining for the necrotic proteins p-MLKL and p-RIP1 was increased and PCNA staining was decreased, indicating that interfering with UBE2L3 expression can promote necroptosis. Moreover, through transfection of UBE2L3 silencing plasmids into osteosarcoma cells in vitro, immunoprecipitation and ubiquitination results demonstrated that UBE2L3 can specifically bind to MLKL. Overexpression of UBE2L3 promoted the ubiquitination of MLKL and reduced its expression. Thus, down-regulation of UBE2L3 could modulate downstream MLKL expression and promote necrosis of osteosarcoma cells.</p><p><strong>Conclusion: </strong>UBE2L3 selectively binds to MLKL, exerting ubiquitination-mediated regulation on downstream MLKL. Decreased expression of UBE2L3 modulates MLKL expression and promotes necrosis, thereby inhibiting osteosarcoma growth.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"63"},"PeriodicalIF":2.5,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy and intraoperative radiation therapy in the management of gastric cancer: a 10-year single center experience.
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2025-02-22 DOI: 10.1186/s12957-025-03678-5
Marwan M Alaswad, Tarek Z Arabi, Asma S Alshahrani, Belal N Sabbah, Heba W Jaamour, Abdullah A AlOtry, Tariq W Saleh, Ziad H Alhosainy, Fadwa H Elkordy, Aya I Elnegali, Mohamed H Tlayjeh, Firas E Kseibi, Ayman Z Azzam, Tarek M Amin

Background: The rationale behind the use of HIPEC involves targeted elimination of microscopic peritoneal metastasis, a common route for GCa dissemination, thereby improving the overall survival and reducing recurrences. Moreover, the reasoning behind the use of IORT is enhanced loco-regional control and, therefore, reducing recurrence rates.

Methods: From February 2013 to June 2023, all GCa patients who underwent HIPEC plus IORT during surgery were included in this study. Median overall survival (OS) and disease-free (DFS) survival were used to evaluate the efficacy of this treatment strategy amongst GCa patients, along with the rate of occurrence and severity of post-operative complications associated with this treatment strategy.

Results: The median OS and DFS were 63 and 87 months, respectively. More than one-third of the patients in our cohort did not develop any post-operative complications. In patients who developed post-operative complications, the median number of post-operative complications was 1 (IQR 1-2). Most encountered complications were Clavien-Dindo (CD) grade II complications (33.33%) and no in-hospital mortality was observed.

Conclusions: This complex, multimodal treatment strategy results in a significantly prolonged OS and DFS when compared to other treatment strategies for gastric cancer patients, with no added morbidity or mortality.

背景:使用 HIPEC 的理由是有针对性地消除微小腹膜转移灶(GCa 传播的常见途径),从而提高总生存率并减少复发。此外,使用 IORT 的理由是加强局部区域控制,从而降低复发率:方法:从 2013 年 2 月至 2023 年 6 月,所有在手术期间接受 HIPEC 加 IORT 的 GCa 患者均纳入本研究。研究采用中位总生存期(OS)和无病生存期(DFS)来评估这一治疗策略在GCa患者中的疗效,以及与这一治疗策略相关的术后并发症的发生率和严重程度:结果:中位OS和DFS分别为63个月和87个月。我们队列中超过三分之一的患者没有出现任何术后并发症。在出现术后并发症的患者中,术后并发症的中位数为1(IQR 1-2)。大多数并发症为克拉维恩-丁多(Clavien-Dindo,CD)II级并发症(33.33%),未观察到院内死亡率:结论:与其他治疗策略相比,这种复杂的多模式治疗策略大大延长了胃癌患者的OS和DFS,而且没有增加发病率或死亡率。
{"title":"Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy and intraoperative radiation therapy in the management of gastric cancer: a 10-year single center experience.","authors":"Marwan M Alaswad, Tarek Z Arabi, Asma S Alshahrani, Belal N Sabbah, Heba W Jaamour, Abdullah A AlOtry, Tariq W Saleh, Ziad H Alhosainy, Fadwa H Elkordy, Aya I Elnegali, Mohamed H Tlayjeh, Firas E Kseibi, Ayman Z Azzam, Tarek M Amin","doi":"10.1186/s12957-025-03678-5","DOIUrl":"10.1186/s12957-025-03678-5","url":null,"abstract":"<p><strong>Background: </strong>The rationale behind the use of HIPEC involves targeted elimination of microscopic peritoneal metastasis, a common route for GCa dissemination, thereby improving the overall survival and reducing recurrences. Moreover, the reasoning behind the use of IORT is enhanced loco-regional control and, therefore, reducing recurrence rates.</p><p><strong>Methods: </strong>From February 2013 to June 2023, all GCa patients who underwent HIPEC plus IORT during surgery were included in this study. Median overall survival (OS) and disease-free (DFS) survival were used to evaluate the efficacy of this treatment strategy amongst GCa patients, along with the rate of occurrence and severity of post-operative complications associated with this treatment strategy.</p><p><strong>Results: </strong>The median OS and DFS were 63 and 87 months, respectively. More than one-third of the patients in our cohort did not develop any post-operative complications. In patients who developed post-operative complications, the median number of post-operative complications was 1 (IQR 1-2). Most encountered complications were Clavien-Dindo (CD) grade II complications (33.33%) and no in-hospital mortality was observed.</p><p><strong>Conclusions: </strong>This complex, multimodal treatment strategy results in a significantly prolonged OS and DFS when compared to other treatment strategies for gastric cancer patients, with no added morbidity or mortality.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"62"},"PeriodicalIF":2.5,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary giant liposarcoma of the gallbladder: a case report and literature review.
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2025-02-22 DOI: 10.1186/s12957-025-03711-7
Yu Yang, Yiwei Hou, Li Yi, Chongyuan Chen, Lihua Tang, Mingzheng Hu, Rongchun Xing

Background: Liposarcoma of the gallbladder is an exceptionally rare malignancy originating from adipose tissue. Its rarity and diagnostic challenges make this case noteworthy. Liposa rcomas exhibit diverse histological subtypes, each with distinct biological behaviors, and there is limited consensus on optimal treatment approaches. This report emphasizes the importance of accurate diagnosis, effective therapeutic strategies, and detailed analysis of clinical outcomes in managing such rare cases.

Case presentation: A 35-year-old woman presented with a two-month history of a palpable abdominal mass accompanied by mild bloating. She reported no significant discomfort, systemic symptoms, or changes in bowel habits. Imaging revealed a large abdominal mass displacing adjacent organs. Magnetic resonance imaging suggested a mixed-signal lesion originating from the gallbladder, and laboratory tests showed elevated inflammatory markers. The patient underwent successful surgical excision of the mass and cholecystectomy. Pathological examination confirmed a well-differentiated liposarcoma closely associated with the gallbladder. Immunohistochemistry indicated positivity for CDK4, MDM2, P16, S-100, and CD34, with a low proliferation index (Ki-67 ~ 10%). Postoperative recovery was uneventful, and the patient showed significant improvement. Long-term management, including genetic testing and follow-up, was planned to monitor recurrence risk and explore potential targeted therapies.

Conclusions: This case underscores the importance of considering rare malignancies like liposarcoma of the gallbladder in the differential diagnosis of abdominal masses. Early diagnosis through imaging and histopathological confirmation is crucial for optimal management. Complete surgical excision remains the cornerstone of treatment, particularly for well-differentiated subtypes, which generally have favorable prognoses. The findings highlight the need for multidisciplinary care and further research into genetic and molecular mechanisms to guide future targeted treatments.

背景:胆囊脂肪肉瘤是一种异常罕见的源自脂肪组织的恶性肿瘤。它的罕见性和诊断上的挑战使这一病例值得关注。脂肪肉瘤表现出不同的组织学亚型,每种亚型都有不同的生物学行为,目前对最佳治疗方法的共识有限。本报告强调了准确诊断、有效治疗策略和详细分析临床结果对处理此类罕见病例的重要性:一名 35 岁的女性患者因腹部可触及肿块伴轻度腹胀就诊两个月。她表示没有明显不适、全身症状或排便习惯改变。影像学检查发现一个巨大的腹部肿块使邻近器官移位。磁共振成像显示,这是一个源自胆囊的混合信号病变,实验室检查显示炎症指标升高。患者成功接受了肿块切除术和胆囊切除术。病理检查证实,这是一种与胆囊密切相关的分化良好的脂肪肉瘤。免疫组化显示 CDK4、MDM2、P16、S-100 和 CD34 阳性,增殖指数较低(Ki-67 ~ 10%)。术后恢复顺利,患者病情明显好转。计划进行长期管理,包括基因检测和随访,以监测复发风险并探索潜在的靶向疗法:本病例强调了在腹部肿块的鉴别诊断中考虑胆囊脂肪肉瘤等罕见恶性肿瘤的重要性。通过影像学检查和组织病理学证实进行早期诊断对于优化治疗至关重要。完全手术切除仍是治疗的基石,尤其是对于分化良好的亚型,其预后通常较好。研究结果强调了多学科治疗和进一步研究遗传和分子机制的必要性,以指导未来的靶向治疗。
{"title":"Primary giant liposarcoma of the gallbladder: a case report and literature review.","authors":"Yu Yang, Yiwei Hou, Li Yi, Chongyuan Chen, Lihua Tang, Mingzheng Hu, Rongchun Xing","doi":"10.1186/s12957-025-03711-7","DOIUrl":"10.1186/s12957-025-03711-7","url":null,"abstract":"<p><strong>Background: </strong>Liposarcoma of the gallbladder is an exceptionally rare malignancy originating from adipose tissue. Its rarity and diagnostic challenges make this case noteworthy. Liposa rcomas exhibit diverse histological subtypes, each with distinct biological behaviors, and there is limited consensus on optimal treatment approaches. This report emphasizes the importance of accurate diagnosis, effective therapeutic strategies, and detailed analysis of clinical outcomes in managing such rare cases.</p><p><strong>Case presentation: </strong>A 35-year-old woman presented with a two-month history of a palpable abdominal mass accompanied by mild bloating. She reported no significant discomfort, systemic symptoms, or changes in bowel habits. Imaging revealed a large abdominal mass displacing adjacent organs. Magnetic resonance imaging suggested a mixed-signal lesion originating from the gallbladder, and laboratory tests showed elevated inflammatory markers. The patient underwent successful surgical excision of the mass and cholecystectomy. Pathological examination confirmed a well-differentiated liposarcoma closely associated with the gallbladder. Immunohistochemistry indicated positivity for CDK4, MDM2, P16, S-100, and CD34, with a low proliferation index (Ki-67 ~ 10%). Postoperative recovery was uneventful, and the patient showed significant improvement. Long-term management, including genetic testing and follow-up, was planned to monitor recurrence risk and explore potential targeted therapies.</p><p><strong>Conclusions: </strong>This case underscores the importance of considering rare malignancies like liposarcoma of the gallbladder in the differential diagnosis of abdominal masses. Early diagnosis through imaging and histopathological confirmation is crucial for optimal management. Complete surgical excision remains the cornerstone of treatment, particularly for well-differentiated subtypes, which generally have favorable prognoses. The findings highlight the need for multidisciplinary care and further research into genetic and molecular mechanisms to guide future targeted treatments.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"61"},"PeriodicalIF":2.5,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unravelling the role of ubiquitin-specific proteases in breast carcinoma: insights into tumour progression and immune microenvironment modulation. 揭示泛素特异性蛋白酶在乳腺癌中的作用:洞察肿瘤进展和免疫微环境调控。
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2025-02-20 DOI: 10.1186/s12957-025-03667-8
Huiyuan Yang, Tingting Sun, Zhenni Sun, Haining Wang, Dongjie Liu, Dapeng Wu, Tao Qin, Mi Zhou

Breast cancer is a prevalent malignancy worldwide, and its treatment has increasingly shifted towards precision medicine, with immunotherapy emerging as a key therapeutic strategy. Deubiquitination, an essential epigenetic modification, is regulated by deubiquitinating enzymes (DUBs) and plays a critical role in immune function and tumor progression. Ubiquitin-specific proteases (USPs), a prominent subgroup of DUBs, are involved in regulating immune cell functions, antigen processing, and T cell development in the context of breast cancer. Certain USPs also modulate the differentiation of immune cells, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), within the breast cancer immune microenvironment. Furthermore, several USPs influence the expression of PD-L1, thus affecting the efficacy of immune checkpoint inhibitors. The overexpression of USPs may promote immune evasion, contributing to the development of treatment resistance. This review elucidates the role of USPs in modulating the immune microenvironment and immune responses in breast cancer. Additionally, it discusses effective strategies for combining USP inhibitors with other therapeutic agents to enhance treatment outcomes. Therefore, targeting USPs presents the potential to enhance the efficacy of immunotherapy and overcome drug resistance, offering a more effective treatment strategy for breast cancer patients.

{"title":"Unravelling the role of ubiquitin-specific proteases in breast carcinoma: insights into tumour progression and immune microenvironment modulation.","authors":"Huiyuan Yang, Tingting Sun, Zhenni Sun, Haining Wang, Dongjie Liu, Dapeng Wu, Tao Qin, Mi Zhou","doi":"10.1186/s12957-025-03667-8","DOIUrl":"10.1186/s12957-025-03667-8","url":null,"abstract":"<p><p>Breast cancer is a prevalent malignancy worldwide, and its treatment has increasingly shifted towards precision medicine, with immunotherapy emerging as a key therapeutic strategy. Deubiquitination, an essential epigenetic modification, is regulated by deubiquitinating enzymes (DUBs) and plays a critical role in immune function and tumor progression. Ubiquitin-specific proteases (USPs), a prominent subgroup of DUBs, are involved in regulating immune cell functions, antigen processing, and T cell development in the context of breast cancer. Certain USPs also modulate the differentiation of immune cells, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), within the breast cancer immune microenvironment. Furthermore, several USPs influence the expression of PD-L1, thus affecting the efficacy of immune checkpoint inhibitors. The overexpression of USPs may promote immune evasion, contributing to the development of treatment resistance. This review elucidates the role of USPs in modulating the immune microenvironment and immune responses in breast cancer. Additionally, it discusses effective strategies for combining USP inhibitors with other therapeutic agents to enhance treatment outcomes. Therefore, targeting USPs presents the potential to enhance the efficacy of immunotherapy and overcome drug resistance, offering a more effective treatment strategy for breast cancer patients.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"60"},"PeriodicalIF":2.5,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated insights into the impact of adjuvant chemotherapy on recurrence and survival after curative resection of liver or lung metastases in colorectal cancer: a rapid review and meta-analysis.
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2025-02-18 DOI: 10.1186/s12957-025-03714-4
Kyota Tatsuta, Mayu Sakata, Tadahiro Kojima, Eisuke Booka, Kiyotaka Kurachi, Hiroya Takeuchi

Background: Colorectal cancer (CRC) frequently metastasizes to the liver and lungs, leading to poor prognosis. Advances in chemotherapy, minimally invasive surgery, and perioperative care have expanded adjuvant chemotherapy (AC) regimens and eligibility for AC. However, the impact of AC after curative resection of distant metastases on recurrence and prognosis remains uncertain. This study evaluated the role of AC in CRC liver and lung metastases, focusing on cases with curative resection based on the latest studies published in the past five years.

Methods: This systematic review followed PRISMA guidelines. Literature searches of Medline and Cochrane Library (2019-2023) identified studies on AC or observation after curative resection of CRC metastases, reporting outcomes such as overall survival (OS) and disease-free survival (DFS). Data analysis was performed using Review Manager and R software, with results expressed as hazard ratios (HR) and 95% confidence intervals (CI).

Results: Seven studies met the eligibility criteria, including one randomized controlled trial and six retrospective studies, encompassing 1580 patients who underwent curative resection (R0) for CRC metastases. This meta-analysis showed a positive trend in OS for the AC group compared to that for the surgery-alone group (HR 0.86, 95% CI: 0.73-1.01; p = 0.06), but the difference was insignificant. AC significantly improved DFS (HR 0.81, 95% CI: 0.66-0.99; p = 0.04). Subgroup analysis indicated that AC significantly improved DFS and tended to improve OS for liver metastasis. In contrast, AC did not improve OS in cases of lung metastasis.

Conclusions: This meta-analysis suggests that AC demonstrated significant positive effects on DFS. Moreover, AC could contribute to improvements in OS. These findings, supported by the latest research, reinforce the recommendation of AC as a valuable strategy for improving both recurrence and survival outcomes in patients with curatively resected distant CRC metastases.

{"title":"Updated insights into the impact of adjuvant chemotherapy on recurrence and survival after curative resection of liver or lung metastases in colorectal cancer: a rapid review and meta-analysis.","authors":"Kyota Tatsuta, Mayu Sakata, Tadahiro Kojima, Eisuke Booka, Kiyotaka Kurachi, Hiroya Takeuchi","doi":"10.1186/s12957-025-03714-4","DOIUrl":"10.1186/s12957-025-03714-4","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) frequently metastasizes to the liver and lungs, leading to poor prognosis. Advances in chemotherapy, minimally invasive surgery, and perioperative care have expanded adjuvant chemotherapy (AC) regimens and eligibility for AC. However, the impact of AC after curative resection of distant metastases on recurrence and prognosis remains uncertain. This study evaluated the role of AC in CRC liver and lung metastases, focusing on cases with curative resection based on the latest studies published in the past five years.</p><p><strong>Methods: </strong>This systematic review followed PRISMA guidelines. Literature searches of Medline and Cochrane Library (2019-2023) identified studies on AC or observation after curative resection of CRC metastases, reporting outcomes such as overall survival (OS) and disease-free survival (DFS). Data analysis was performed using Review Manager and R software, with results expressed as hazard ratios (HR) and 95% confidence intervals (CI).</p><p><strong>Results: </strong>Seven studies met the eligibility criteria, including one randomized controlled trial and six retrospective studies, encompassing 1580 patients who underwent curative resection (R0) for CRC metastases. This meta-analysis showed a positive trend in OS for the AC group compared to that for the surgery-alone group (HR 0.86, 95% CI: 0.73-1.01; p = 0.06), but the difference was insignificant. AC significantly improved DFS (HR 0.81, 95% CI: 0.66-0.99; p = 0.04). Subgroup analysis indicated that AC significantly improved DFS and tended to improve OS for liver metastasis. In contrast, AC did not improve OS in cases of lung metastasis.</p><p><strong>Conclusions: </strong>This meta-analysis suggests that AC demonstrated significant positive effects on DFS. Moreover, AC could contribute to improvements in OS. These findings, supported by the latest research, reinforce the recommendation of AC as a valuable strategy for improving both recurrence and survival outcomes in patients with curatively resected distant CRC metastases.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"56"},"PeriodicalIF":2.5,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A suspension surgical space construction method involving a gasless transoral endoscopic thyroidectomy vestibular approach: a single-center experience.
IF 2.5 3区 医学 Q3 ONCOLOGY Pub Date : 2025-02-18 DOI: 10.1186/s12957-025-03708-2
Xuren Sheng, Jing Fang, Gongpu Chen, Wang Li, Shengying Wang

Objective: This study aimed to summarize and explore how to establish a good surgical space via a gasless transoral endoscopic thyroidectomy vestibular approach (TOETVA) to facilitate smooth surgical progress.

Methods: This study was conducted between January 2022 and December 2023. The study involved 281 patients with papillary thyroid carcinoma who underwent gasless TOETVA at The First Affiliated Hospital of the University of Science and Technology of China. The suspension method was used to establish the surgical space during the operation. The key steps and difficulties of surgical space construction were summarized, and the clinicopathological characteristics and surgical complications of the patients were analyzed.

Results: The mean surgical duration was 167.86 ± 25.38 min, and the time needed to create the surgical space (from incision of the lip mucosa to incision of the anterior border of the neck) was 17.82 ± 9.44 min. During the construction of the surgical space, there was 1 case of thermal skin burn and 2 cases of bleeding from the anterior jugular vein, with no permanent injury to the mental nerve.

Conclusion: In the gasless TOETVA, the suspension method of surgical space construction was employed to rapidly establish a stable three-dimensional operating space that was less prone to collapse, thus facilitating the smooth implementation of subsequent surgical procedures.

{"title":"A suspension surgical space construction method involving a gasless transoral endoscopic thyroidectomy vestibular approach: a single-center experience.","authors":"Xuren Sheng, Jing Fang, Gongpu Chen, Wang Li, Shengying Wang","doi":"10.1186/s12957-025-03708-2","DOIUrl":"10.1186/s12957-025-03708-2","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to summarize and explore how to establish a good surgical space via a gasless transoral endoscopic thyroidectomy vestibular approach (TOETVA) to facilitate smooth surgical progress.</p><p><strong>Methods: </strong>This study was conducted between January 2022 and December 2023. The study involved 281 patients with papillary thyroid carcinoma who underwent gasless TOETVA at The First Affiliated Hospital of the University of Science and Technology of China. The suspension method was used to establish the surgical space during the operation. The key steps and difficulties of surgical space construction were summarized, and the clinicopathological characteristics and surgical complications of the patients were analyzed.</p><p><strong>Results: </strong>The mean surgical duration was 167.86 ± 25.38 min, and the time needed to create the surgical space (from incision of the lip mucosa to incision of the anterior border of the neck) was 17.82 ± 9.44 min. During the construction of the surgical space, there was 1 case of thermal skin burn and 2 cases of bleeding from the anterior jugular vein, with no permanent injury to the mental nerve.</p><p><strong>Conclusion: </strong>In the gasless TOETVA, the suspension method of surgical space construction was employed to rapidly establish a stable three-dimensional operating space that was less prone to collapse, thus facilitating the smooth implementation of subsequent surgical procedures.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"58"},"PeriodicalIF":2.5,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World Journal of Surgical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1